Current Editions
Fueled by cancer, obesity and CV deals, $1B+ takeouts are on the rise
Pharma needs, IPO drought feed 10-figure M&A
Data Byte
Product Development
Semaglutide was supposed to quench CNS inflammation — it didn’t
The GLP-1’s anti-inflammatory effects in the periphery did not translate to the brain
Another Praxis win provides much-needed progress in rare genetic epilepsies
Registrational study of Praxis’ relutrigine stopped early for efficacy
Deals
Are M&A buyers ready to spend more on earlier-stage deals? A Perspective
A handful of recent transactions appear to show an appetite for assets, pipelines and platforms further upstream
Finance
Biocytogen lands on STAR as NASDAQ plays parlay data into cash: Finance Report
San Diego’s Protego builds out syndicate with $130M series B and more venture rounds
BioCentury ISSN 1097-7201